

## CHAPTER 24

# Indications and Outcomes of Gastrointestinal Endoscopy

Constance E. Ruhl, M.D., Ph.D.; and James E. Everhart, M.D., M.P.H.

Through diagnosis and management, endoscopy plays a role in nearly all GI diseases as well as a crucial role in clinical research. It is estimated that more than 20 million GI endoscopies are performed yearly in the United States.<sup>1</sup> There is no single national endoscopic database that can provide accurate population-based information on the absolute number of GI endoscopies and their indications and diagnostic outcomes. To remedy this important gap in knowledge on the burden of GI disease, data were obtained from the Clinical Outcomes Research Initiative's (CORI) National Endoscopic Database (NED). For more than 10 years, this project has collected and analyzed computerized endoscopic records gathered from diverse endoscopic practices throughout the United States. Pediatric procedures are not represented, and the participating sites are overrepresented by veteran and military facilities. Nevertheless, the patterns of endoscopy in NED have been shown to be quite similar to that of a national sample of the Medicare population and may well be applicable to the United States as a whole.<sup>2</sup> There is no independent confirmation of the indications and diagnoses reported by the endoscopist on the endoscopy record, although the report is frequently included in the medical record and used for billing.

For this report, endoscopic data were obtained for the period 2001–2005. The number of patients receiving the various endoscopic procedures, along with the practices and practice sites where the procedures were conducted, is shown in Table 1. Of the 885,593 procedures performed during this period, 61.2 percent were colonoscopies, 30.6 percent were esophagogastroduodenoscopies (EGD), 6.3 percent were flexible sigmoidoscopies, 1.0 percent were endoscopic retrograde cholangiopancreatography (ERCP), and 0.8 percent were endoscopic ultrasonographies (EUS). Colonoscopy, flexible sigmoidoscopy, and EGD were primarily performed within community or health maintenance organization

(HMO) practices in hospital or ambulatory surgery centers. The more specialized procedures of ERCP and EUS were more likely to have been performed in academic centers and almost exclusively in the hospital. Age 50–59 years was the peak age group for all the procedures. There was some ethnic variation in likelihood of receiving a particular procedure, relative to all procedures. Non-Hispanic whites were more likely to have undergone colonoscopy (85.9 percent) and EUS (86.9 percent), non-Hispanic blacks (13.3 percent) and Asian-Pacific Islanders (2.2 percent) flexible sigmoidoscopy, and Native Americans (6.0 percent) and Hispanics (12.4 percent) ERCP. Excluding Veterans Affairs (VA) facilities, the majority of procedures were performed on women.

Of the 101 sites providing data to NED during 2001–2005, 36 did so throughout the 5-year period. At these “stable” sites, the total number of procedures increased by 34.1 percent from 2001 to 2005, but trends differed by procedure (Figure 1). Colonoscopy increased 63.4 percent, partly at the expense of flexible sigmoidoscopy, which decreased by 60.0 percent. EGD increased by 20.3 percent. The frequency of each of these procedures peaked at age 50–59 years, but more so for colonoscopy (Figure 2). At the stable sites, the growth in colonoscopy from 2001 to 2005 was concentrated among this age group and to a lesser extent among persons ages 60–69 years (Figure 3). The number of colonoscopies among other age groups changed little. In contrast, the number of sigmoidoscopies at stable sites declined appreciably among persons ages 40–79 years, but most among those ages 50–79 (Figure 4).

The distribution of indications for all colonoscopies and sigmoidoscopies is shown in Table 2. Because there could be more than one indication for a procedure, the totals of the percentages exceeded 100 percent. Broadly speaking, surveillance and symptoms were

more often listed as indications for colonoscopy than for sigmoidoscopy, while screening was a more frequent indication for sigmoidoscopy than for colonoscopy. Suspected bleeding was the most common indication for colonoscopy (29.7 percent), followed by screening of persons at routine risk of colorectal cancer (21.6 percent), surveillance of adenomatous polyps (13.5 percent), and screening for persons with a family history of colorectal cancer (12.1 percent). These most common indications for colonoscopy indicate that concern over possible colorectal cancer was the predominant reason for colonoscopy. The same statement can be made for sigmoidoscopy, except that a high percentage (47.4 percent) were performed for persons at routine risk of colorectal cancer.

The findings among persons who had colonoscopies or sigmoidoscopies are shown in Table 3. The most interesting group is the column of colonoscopic findings among persons at routine risk only, among whom findings should not have been influenced by symptoms or other indications for the procedure. As long as all abnormalities were recorded, these may be considered the prevalence of such findings in the general population. Common but benign conditions such as diverticulosis and hemorrhoids may not have been recorded if a more serious problem was diagnosed. Notably, 21.0 percent of examinations were normal and 6.4 percent found a polyp of at least 1 centimeter or a suspected malignancy. Figure 5 demonstrates colonoscopic findings among persons at routine risk according to age group. Diverticulosis, the most common finding, steadily increased in prevalence from age 50–59 years to age 80 years and older, at which point it was found on 71.4 percent of examinations. Increasing in prevalence with age, but not as quickly as diverticulosis, were polyps of all sizes and number, and hemorrhoids. The prevalence of normal examinations fell from 36.2 percent at age 20–39 years to 10.2 percent at 80 years and above. There was a higher prevalence of polyps among men than women at routine risk (Figure 6), but no other particular differences by sex. Hemorrhoids were more common among Hispanics, but no other racial or ethnic differences were evident (Figure 7).

In contrast to the uneven increase in utilization of colonoscopy across age groups, EGD use

increased modestly across all age groups at stable sites (Figure 8). The indications for EGD at all NED sites are shown in Table 4. These indications were not mutually exclusive and included groupings of symptoms, notably alarm symptoms (weight loss, vomiting, or bleeding) and bleeding (anemia, iron deficiency, melena, hematemesis, hematochezia, positive fecal occult blood test, or suspected upper GI bleed). The most common indications for EGD were reflux symptoms (28.3 percent), alarm symptoms (27.7 percent), dysphagia (20.5 percent), signs of bleeding (20.4 percent), and abdominal pain or bloating (20.1 percent). More than 40 percent of examinations had normal findings (Table 5). The most common diagnostic abnormalities were mucosal abnormality, hiatal hernia, and esophageal inflammation, each of which is characteristic of GERD. The next three most common diagnoses, stricture/stenosis, Barrett's esophagus, and ulcer, can be consequences of GERD. Combining these diagnoses, it can be inferred that the large majority of abnormal findings on EGD are associated with GERD.

ERCP findings from 2001–2005 are shown in Table 6. Because there were fewer than 10,000 ERCP reports from relatively few centers, the generalizability of the results is questionable. Also, some important information appeared in free text fields in the report, making interpretation more difficult. Nevertheless, it appeared that ductal abnormalities and obstruction to flow were the most common findings on ERCP, and that one-third of examinations were normal. EUS was performed too infrequently and at too few sites to present information on either indication or results.

<sup>1</sup> Seeff LC, Richards TB, Shapiro JA, Nadel MR, Manninen DL, Given LS, Dong FB, Wings LD, McKenna MT. How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity. *Gastroenterology*. 2004;127:1670–1677.

<sup>2</sup> Sonnenberg A, Amorosi SL, Lacey MJ, Lieberman DA. Patterns of endoscopy in the United States: analysis of data from the Centers for Medicare and Medicaid Services and the National Endoscopic Database. *Gastrointestinal endoscopy*. 2008;67:489–496.


**Table 1.** Characteristics of Endoscopy Sites and Persons Undergoing Endoscopic Procedures, 2001–2005

		COLONOSCOPY	EGD	FLEXIBLE SIGMOIDOSCOPY	ERCP	EUS
Number of Patients		542,650	270,957	55,708	9,333	6,945
Number of Practices		76	77	72	40	23
Number of Sites		101	101	96	44	25
SITE CHARACTERISTICS (Percentage)						
TYPE OF ENDOSCOPY SITE	Community/HMO	78.1	72.8	58.5	40.1	2.9
	Academic	11.3	14.6	16.6	41.1	66.5
	VA/Military	10.6	12.6	24.9	18.8	30.6
TYPE OF FACILITY	Office	1.7	2.7	1.1	<0.1	0
	Hospital	40.9	49.7	51.3	96.7	100
	Ambulatory Surgery Center	57.4	47.6	47.7	3.3	<0.1
PATIENT CHARACTERISTICS (Percentage)						
AGE (Years)	20–29	1.7	4.6	5.6	9.2	2.3
	30–39	4.0	9.4	8.6	10.3	5.3
	40–49	11.7	17.4	12.2	14.1	13.1
	50–59	32.9	23.1	34.6	19.3	24.3
	60–69	25.6	19.5	19.8	16.5	24.1
	70–79	18.4	17.5	13.6	18.3	22.8
	80+	5.9	8.6	5.6	12.4	8.1
RACE/ETHNICITY	Non-Hispanic White	85.9	81.3	78.2	72.0	86.9
	Non-Hispanic Black	6.4	7.3	13.3	7.5	5.0
	Asian/Pacific Islander	1.5	2.0	2.2	1.8	1.8
	American Indian/Alaska Native	0.8	1.2	0.9	6.0	0.4
	Multiracial Non-Hispanic	0.2	0.2	0.6	0.3	0.3
	Hispanic	5.3	8.0	4.8	12.4	5.6
SEX	Female	49.6	51.4	41.0	52.0	40.7
	Male	50.4	48.6	59.0	48.0	59.3
SEX (Excluding VA/Military)	Number of Patients	485,085	236,848	41,839	7,577	4,819
	Female	54.3	57.2	52.7	61.1	51.6
	Male	45.8	42.8	47.3	38.9	48.4

EGD = Esophagogastroduodenoscopy; ERCP = Endoscopic retrograde cholangiopancreatography; EUS = Endoscopic ultrasonography; VA = Department of Veterans Affairs


SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Figure 1.** Number of Endoscopic Procedures at Stable Sites (N=36) by Year, 2001–2005




EGD = Esophagogastroduodenoscopy  
 SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative


**Figure 2.** Number of Endoscopic Procedures by Age, 2001–2005



EGD = Esophagogastroduodenoscopy  
 SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Figure 3.** Number of Colonoscopies at Stable Sites (N=36) by Age and Year, 2001–2005

SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Figure 4.** Number of Flexible Sigmoidoscopies at Stable Sites (N=36) by Age and Year, 2001–2005

SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Table 2.** Indications for Colonoscopy and Flexible Sigmoidoscopy, 2001–2005

INDICATION	PERCENTAGE <sup>1</sup>	
	COLONOSCOPY (N=542,650)	FLEXIBLE SIGMOIDOSCOPY (N=55,708)
<b>SURVEILLANCE</b>		
Surveillance of Adenomatous Polyps	13.5	2.4
Surveillance of Colorectal Cancer	2.0	1.0
Surveillance of Ulcerative Colitis	0.9	1.0
Surveillance of Crohn's Disease	0.6	0.4
Established Crohn's Disease	0.2	0.2
Established Ulcerative Colitis	0.2	0.6
<b>SCREENING</b>		
Routine Risk Only	21.6	47.4
Family History of Colorectal Cancer	12.1	1.0
Family History of Polyps	2.8	0.3
<b>SYMPTOMS</b>		
Bleeding Group <sup>2</sup>	29.7	21.7
Irritable Bowel Syndrome Cluster <sup>3</sup>	18.2	15.0
Hematochezia	17.9	20.4
Abdominal Pain/Bloating	9.1	5.4
Diarrhea	7.6	9.9
Positive Fecal Occult Blood Test	7.2	0.7
Change in Bowel Habits	7.1	1.6
Anemia	5.7	0.9
Constipation	5.4	4.5
Weight Loss	1.6	0.5
Melena	0.7	0.2
Iron Deficiency Without Anemia	0.3	<0.1
<b>FOLLOWUP OF DIAGNOSIS</b>		
Polyp Found on Flexible Sigmoidoscopy	1.5	0.2
Abnormal Study	1.0	1.2
History of Non-Gastrointestinal Cancer	0.8	0.3
Suspected Inflammatory Bowel Disease	0.5	0.6
Polyp Found on Barium Enema	0.2	0.1
Polyp Found on Previous Colonoscopy	0.2	0.4
<b>OTHER</b>	6.5	11.5

<sup>1</sup> Indication categories are not mutually exclusive.<sup>2</sup> Bleeding group = one or more of the following symptoms: anemia or iron deficiency, positive fecal occult blood test, hematochezia, melena.<sup>3</sup> Irritable bowel syndrome cluster = one or more of the following symptoms: diarrhea; constipation; abdominal pain/bloating; change in bowel habits, excluding surveillance of, or established Crohn's disease or ulcerative colitis; weight loss; and bleeding (anemia or iron deficiency, positive fecal occult blood test, hematochezia, melena).

**Table 3.** Colonoscopy Findings in the Total Population and Persons at Routine Risk Only, and Flexible Sigmoidoscopy Findings, 2001–2005


FINDING	PERCENTAGE <sup>1</sup>		
	COLONOSCOPY		FLEXIBLE SIGMOIDOSCOPY (N=55,708)
	Total Population (N=542,650)	Routine Risk Only (N=117,422)	
Diverticulosis	42.8	45.0	22.3
Hemorrhoids	39.6	34.2	31.7
Polyp	35.9	37.4	16.2
Normal Exam/No Findings	17.6	21.0	30.5
Polyp > 9mm/Suspected Malignant Tumor	7.6	6.4	3.4
Multiple Polyps	7.2	7.2	2.8
Mucosal Abnormality-Colitis	5.2	1.4	7.8
Tumor	1.2	0.4	0.9
Angiodysplasia (AVM)	1.1	0.7	0.3
Other Finding	9.8	6.6	12.1

AVM = arteriovenous malformation

<sup>1</sup> Finding categories are not mutually exclusive.


SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Figure 5.** Colonoscopy Findings in Persons at Routine Risk by Age, 2001–2005



SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative


**Figure 6.** Colonoscopy Findings in Persons at Routine Risk by Sex, 2001–2005



SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative




**Figure 7.** Colonoscopy Findings in Persons at Routine Risk by Race/Ethnicity, 2001–2005



SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Figure 8.** Number of Esophagogastroduodenoscopy (EGD) Procedures at Stable Sites (N=36) by Age and Year, 2001–2005



EGD = Esophagogastroduodenoscopy

SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Table 4.** Indications for Esophagogastroduodenoscopy (EGD) (N=270,957), 2001–2005

INDICATION	PERCENTAGE <sup>1</sup>
<b>SURVEILLANCE</b>	
Surveillance of Barrett’s Esophagus	3.1
Surveillance of Gastric Ulcer	1.0
Surveillance of Varices	0.9
Surveillance of <i>Helicobacter Pylori</i>	0.3
Surveillance of Duodenal Ulcer	0.2
Surveillance of Gastric Polyps	0.2
<b>SCREENING</b>	
Screening for Barrett’s Esophagus	1.5
Screening for Varices	0.9
<b>SYMPTOMS</b>	
Reflux Symptoms/Heartburn	28.3
Alarm Symptoms <sup>2</sup>	27.7
GERD <sup>3</sup>	22.3
Dyspepsia/Abdominal Pain <sup>4</sup>	21.6
Dysphagia	20.5
Bleeding Cluster <sup>5</sup>	20.4
Abdominal Pain/Bloating	20.1
Anemia	10.5
Dyspepsia	9.7
Nausea	6.7
Vomiting	4.9
Melena	4.6
Weight Loss	4.0
Chest Pain	3.9
Hematemesis	2.8
Diarrhea	2.4
Early Satiety	1.3
Hematochezia	0.9
Anorexia	0.8
Odynophagia	0.7
Pulmonary Symptoms	0.7
Iron Deficiency Without Anemia	0.5
Malabsorption	0.2
Feeding Refusal	0.1

**Table 4.** Indications for Esophagogastroduodenoscopy (EGD) (N=270,957), 2001–2005 (continued)

INDICATION		PERCENTAGE <sup>1</sup>
<b>FOLLOWUP OF DIAGNOSIS</b>	Positive Fecal Occult Blood Test	2.7
	Suspected Upper Gastrointestinal Bleed	2.5
	Abnormal Study/Exam/Results	2.1
	Therapeutic Intervention	1.2
	Evaluation of Suspected Varices	0.8
	Suspected Barrett's Esophagus	0.4
	Family History of Cancer	0.3
	Prior Upper Gastrointestinal Cancer	0.2
	Gastrointestinal Symptoms in Immunocompromised Host	0.1
	Personal History of Other Upper Gastrointestinal Condition	0.1
	Evaluation of Crohn's Disease	< 0.1
<b>OTHER</b>	8.4	

<sup>1</sup> Indication categories are not mutually exclusive.

<sup>2</sup> Alarm symptoms = weight loss, vomiting, bleeding cluster.

<sup>3</sup> GERD = reflux symptoms, excluding dysphagia and surveillance of Barrett's esophagus.

<sup>4</sup> Dyspepsia/abdominal pain = dyspepsia and/or abdominal pain/bloating, excluding reflux symptoms; dysphagia; and surveillance of Barrett's esophagus.

<sup>5</sup> Bleeding cluster = any of the following indications: anemia, iron deficiency without anemia, melena, hematemesis, hematochezia, positive fecal occult blood test, suspected upper gastrointestinal bleed.

SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Table 5.** Esophagogastroduodenoscopy (EGD) Findings (N=270,957), 2001–2005

FINDING	PERCENTAGE <sup>1</sup>
Normal Exam	41.5
Mucosal Abnormality	38.8
Hiatal Hernia	33.4
Esophageal Inflammation	17.8
Stricture/Stenosis	9.9
Barrett's Esophagus	6.7
Ulcer	6.3
Polyp	4.5
Varices	2.8
Prior Surgery	2.6
Foreign Body/Retained Food	2.1
Nodule	2.0
Anatomical Deformity	1.0
Tumor	0.9
Arteriovenous Malformation	0.9
Healed Ulcer	0.5
Other Finding	18.0

<sup>1</sup> Finding categories are not mutually exclusive.

SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

**Table 6.** Endoscopic Retrograde Cholangiopancreatography (ERCP) Findings (N=9,333), 2001–2005

FINDING	PERCENTAGE <sup>1</sup>
Ductal Dilation	37.2
Normal Exam	34.6
Stones	25.9
Stricture/Stenosis	18.1
Filling Defect	8.5
Duodenal Diverticulum	5.7
Stent	4.6
Leak/Extravasation	3.1
Irregularity	2.3
Tumor	1.5
Pancreas Divisum	1.0
Pancreatitis	0.7
Extrinsic Compression	0.5
Pancreatic Pseudocyst	0.4
Cholangitis	0.3
Other Finding	28.2

<sup>1</sup> Finding categories are not mutually exclusive.

SOURCE: National Endoscopy Database/Clinical Outcomes Research Initiative

